Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Walgreens Volatility Is 'Noise'

RADCQ, WBA

Jefferies’ Brian Tanquilut maintains a bullish stance on Walgreens Boots Alliance Inc (NASDAQ: WBA), stating that the stock volatility over the past week, driven by speculations regarding FTC concerns with the pending Rite Aid Corporation (NYSE: RAD) deal, is just near-term “noise.”

Tanquilut maintains a Buy rating on Walgreens Boots Alliance, with a price target of $95.

The Deal

“While completion of the RAD deal would be a positive for the stock and WBA's LT growth, we believe the NT thesis on the stock still rests on volume acceleration, G&A cost controls, and FCF uptick,” the analyst mentioned.

“Last Friday, Bloomberg News noted that the FTC is concerned about WBA's RAD acquisition despite the proposed divestiture of 865 stores, which drove volatility in WBA shares,” the analyst explained.

Although it is difficult to determine the current stand taken by the FTC, speculations have been rising, given that the deadline for the deal is Friday.

“Our view is that absent a final FTC blockage, WBA and RAD would be open to extending the merger deadline as both parties remain committed to the deal,” Tanquilut stated.

If Deal Falls Through

If the deal is blocked, Walgreens is likely to mitigate the negative headline and lost accretion with a large share buyback worth over $2 billion.

“Our math suggests that resuming WBA's existing buyback ($2.3 billion remaining authorization) could add $0.11 to CY17 EPS and make up for the RAD EPS accretion ($0.05–$0.12) that mgmt. baked into FY17 guidance,” the analyst noted.

Image Credit: By Michael Rivera (Own work) [CC BY-SA 4.0], via Wikimedia Commons

Latest Ratings for WBA

Date Firm Action From To
Oct 2016 Wells Fargo Initiates Coverage On Outperform
Oct 2016 Jefferies Upgrades Hold Buy
Oct 2016 UBS Initiates Coverage on Buy

View More Analyst Ratings for WBA
View the Latest Analyst Ratings



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today